APDS - A New Approach to Treatment of Relapsed Refractory HCL

The primary endpoints of reduced lymphadenopathy and improved naive B cell count may not represent clinically meaningful results. Newman and Teachey conclude that this study sets a strong example for other rare diseases, wherever it should be made to evaluate precision therapies in randomized Phase 3 trials. Next up, we'll discuss the findings from the blood article entitled, Dabrafenib plus Trimetinib, in patients with Relapsed Refractory B-Raph, V600E, Mutation Positive, Harry Cell Leukemia.